Stay updated on HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Sign up to get notified when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.

Latest updates to the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated to v3.3.4; prior tag v3.3.3 is no longer displayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedLocations section updated to include Guangdong and Zhejiang as study sites. The HHS Vulnerability Disclosure link in the footer has been removed.SummaryDifference0.3%

- Check51 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study details, eligibility criteria, locations, or contacts were affected.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the site-wide notice about government funding and operating status. The page now displays the study details without that banner.SummaryDifference0.4%

- Check80 days agoChange DetectedNo additions or deletions were detected; the study details, eligibility criteria, and contact information appear unchanged.SummaryDifference0.4%

- Check102 days agoChange DetectedCore content updated to v3.2.0 with a new government funding operating-status notice for NIH Clinical Center; previous v3.1.0 deletion removed the old version tag.SummaryDifference3%

Stay in the know with updates to HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.